|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the association of NRF2, HMOX-1, NQO1, and MT gene polymorphisms with CVD risk factors in Thais.
|
31332605 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The upregulation of antioxidant enzyme heme oxygenase-1 (HMOX1) in endothelial cells is considered to be beneficial in cardiovascular disease.
|
31644887 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The present study evaluates the capacity of ET-1 to affect endothelin-1-associated hypertrophic activity and decreased expression of heme oxygenase-1 by H9c2 rat cardiomyoblasts in vitro, corresponding to in vivo processes underlying cardiovascular diseases (CVDs).
|
29354880 |
2018 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
This review aimed to describe the molecular mechanisms involved in the induction of HO-1 under different statins in the most common CVD.
|
27033195 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Strikingly, these features relate to numerous genes with a key role in the pathogenesis of cardiovascular disease, especially thrombin signaling, including the thrombin receptors on platelets F2R (coagulation factor II (thrombin) receptor; PAR1) and GP5 (glycoprotein 5), as well as HMOX1 (haem oxygenase 1) and BCL2L1 (BCL2-like 1) which are involved in protection against oxidative stress and apoptosis, respectively.
|
28225026 |
2017 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Heme oxygenase-1 (HO-1) is one of the genetic factors reported to play a role in cardiovascular disease and the patency of vascular access.
|
27312759 |
2016 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We performed a systematic review of all literature from 1997 to 2013 on the association of the HO-1 (GT)n and cardiovascular disease (CVD).
|
26483091 |
2016 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Subjects with ≥32 tandem repeats on both HO-1 alleles compared with the rest of the population (recessive trait) featured substantially increased cardiovascular disease risk (hazard ratio [95% confidence interval], 5.45 [2.39, 12.42]; P<0.0001), enhanced atherosclerosis progression (median difference in atherosclerosis score [interquartile range], 2.1 [0.8, 5.6] versus 0.0 [0.0, 2.2] mm; P=0.0012), and a trend toward higher levels of oxidized phospholipids on apolipoprotein B-100 (median oxidized phospholipids/apolipoprotein B level [interquartile range], 11364 [4160, 18330] versus 4844 [3174, 12284] relative light units; P=0.0554).
|
25359861 |
2015 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The HMOX1 genotypes were not found to be associated with CAD, but the short allele carrier group contained more individuals with hsCRP values reflecting low risk of cardiovascular disease in the Korean population.
|
25187885 |
2014 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the temporal requirements for protection by HO-1 induction relative to injury have not been investigated, but are essential to employ HO-1 as a therapeutic strategy in human cardiovascular disease states.
|
23732814 |
2013 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, HO-1 has a great therapeutic potential for cardiovascular disease.
|
21091076 |
2011 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The relationship of HO-1 genotype with arsenic-associated cardiovascular disease has not been studied.
|
20708634 |
2010 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Human HO1 promoter polymorphisms causing weaker upregulation of the enzyme are associated with increased cardiovascular disease and increased serum ferritin.
|
18619522 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study).
|
19389234 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This review discusses the implications of HO-1 delivery during the early stages of cardiovascular system injury or in early vascular pathology, and suggests that pharmacological agents that regulate HO activity or HO-1 gene delivery itself may become powerful tools for preventing the onset or progression of various cardiovascular diseases.
|
19384082 |
2009 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we present some of the emerging evidence in support of the view that the induction of the HO-1 gene may be a new opportunity to target the pathophysiology of CVD, with therapeutic implications for management.
|
18786476 |
2008 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Most studies have focused on the role of HO-1 in cardiovascular diseases, in which its significant, beneficial activity is well recognized.
|
17822372 |
2007 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A functional GT dinucleotide length polymorphism in the haem oxygenase-1 (HO-1) gene promoter is thought to be involved in the pathogenesis of cardiovascular disease.
|
16313248 |
2005 |